Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
about
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell TransplantationAlternative donor transplant of benign primary hematologic disordersSuccessful autologous cord blood transplantation in a child with acquired severe aplastic anemiaEvolving hematopoietic stem cell transplantation strategies in severe aplastic anemia.Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation studyAlemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia.Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia.Less could be better: the case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia.Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning.Outcomes and healthcare utilization in children and young adults with aplastic anemia: A multiinstitutional analysis.Diagnosis and Treatment of Aplastic Anemia.Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia
P2860
Q26740251-290EE47F-802E-44F3-85C9-4414F8271519Q26823398-6695F14C-BBAD-4E4F-BC34-72056771227FQ34241314-C1374E4A-9A6B-4C7B-9AAC-9762D84D3E2DQ36497220-ECDF2204-7FE4-4ED5-BC28-986EE563B170Q36884109-92203DC8-7BBE-40EB-8DFF-F4687DA08CDEQ41441009-A36C1049-4ABE-403A-951A-0616B823AFF3Q43445845-84FF34FF-898D-47C4-84CC-7737BDEDDA51Q43928679-00517298-3798-4D70-94DF-37F5F319402CQ47126486-F0BAF2D9-EE0D-4FE0-B956-A710F2171D02Q47770634-9BD7E80F-1F33-47A8-A102-49521ABF60EDQ47836932-04D8D197-53F3-4E47-B9CE-93D5F3114205Q58449850-9B3D670A-41F6-416D-BF00-6943B515768F
P2860
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Fludarabine-based conditioning ...... cyclophosphamide dose levels.
@en
type
label
Fludarabine-based conditioning ...... cyclophosphamide dose levels.
@en
prefLabel
Fludarabine-based conditioning ...... cyclophosphamide dose levels.
@en
P2093
P2860
P1476
Fludarabine-based conditioning ...... cyclophosphamide dose levels.
@en
P2093
Dennis L Confer
Eric S Leifer
Iris D Gersten
John M McCarty
Joseph H Antin
Marian Ewell
Mary Eapen
Mary M Horowitz
Michael A Pulsipher
Mitchell Horwitz
P2860
P304
P356
10.1016/J.BBMT.2012.04.014
P577
2012-04-27T00:00:00Z